1 The ability of a series of homologues and analogues of palmitoylethanolamide to inhibit the uptake and fatty acid amidohydrolase (FAAH) H]-AEA to a similar extent as AM404, whereas palmitoylethanolamide, palmitoylcyclohexamide and R-palmitoyl-(2-methyl)ethanolamide were less eective. 7 These data provide useful information upon the ability of palmitoylethanolamide analogues to act as`entourage' compounds. Palmitoylisopropylamide may prove useful as a template for design of compounds that reduce the cellular accumulation and metabolism of AEA without aecting either CB 1 or CB 2 receptors.
Introduction
It is now well established that the endogenous fatty acid amide anandamide (AEA) has, as a result of its actions upon cannabinoid and vanilloid receptors, a number of interesting pharmacological properties including eects on nociception (Calignano et al., 1998; Jaggar et al., 1998; Richardson et al., 1998; Raa et al., 1999; Gauldie et al., 2001) , memory processes (Terranova et al., 1995; Mallet & Beninger, 1998) , lung function , spasticity (Baker et al., 2001) and cell proliferation Sarker et al., 2000; MacCarrone et al., 2000) (for a recent review of the therapeutic potential of AEA and related endocannabinoids, see Piomelli et al., 2000) .
AEA is metabolised by a fatty acid amide hydrolase (Deutsch & Chin, 1993) , and inhibition of this enzyme by phenylmethylsulphonyl¯uoride and palmitylsulphonyl¯uor-ide, have been shown to potentiate the pharmacological actions of AEA both in vitro and in vivo (Childers et al., 1994; Pertwee et al., 1995; Compton & Martin, 1997; Giord et al., 1999) . This raises the possibility that compounds interfering with the metabolism of AEA may be therapeutically useful. A number of FAAH inhibitors have been described, often based on the structure of AEA itself (see e.g. Koutek et al., 1994; Bisogno et al., 1998; Boger et al., 2000b) , although an inherent disadvantage in this approach is that some of the compounds are per se active at cannabinoid receptors. An alternative approach is to prevent the metabolism of AEA with compounds related to palmitoy(IC 50 7 nM) with rather weak eects on the binding of the CB agonist [ 3 H]-CP 55,940 to rat forebrain CB 1 receptors (Deutsch et al., 1997) .
An alternative to transition state inhibitors such as sulphonyl¯uoride analogues of fatty acid amides is to use homologues of palmitoylethanolamide to compete with [ 3 H]-AEA for the FAAH active site. In a recent study, a number of homologues and analogues of palmitoylethanolamide were synthesized and demonstrated not to be active towards either CB 1 or CB 2 receptors at concentrations of 1 mM, ; see also Lang et al., 1999 for data with stearoylethanolamide and oleoylethanolamide). In the present study, we have investigated the abilities of these compounds to prevent the FAAH-catalysed metabolism of AEA and their interference with cellular AEA uptake, in the hope of identifying possible therapeutically useful`entourage' compounds. In addition, we have investigated a novel N-methyl analogue of palmitoylethanolamide, R-palmitoyl-(2-methyl)-ethanolamide. The structures of palmitoylethanolamide, R-palmitoyl-(2-methyl)ethanolamide and the two compounds found to show the best activity, palmitoylisopropylamide (C16:0) and oleoylethanolamide (C18:1), are shown in Figure 1 .
Methods

Compounds
Anandamide [ethanolamine-1- ) were obtained from New England Nuclear, Boston, MA, U.S.A. Decanoylethanolamide (C10:0), lauroylethanolamide (C12:0), myristoylethanolamide (C14:0), palmitoylethanolamide (C16:0), palmitoylbutylamide (C16:0), palmitoylisopropylamide (C16:0), palmitoylcyclohexamide (C16:0) and oleoylethanolamide (C18:1) were synthesized as earlier described by . Nonradioactive anandamide (arachidonoylethanolamide, AEA), (R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide (R1-methanandamide), heptadecanoylethanolamide (C17:0), stearoylethanolamide (C18:0), palmitoyltri¯uoromethyl ketone (PTMK) and arachidonyl-serotonin were purchased from Cayman Chemical Company (Ann Arbor, MI, U.S.A.). Rpalmitoyl-(2-methyl)ethanolamide (C16:0) was custom synthesized by the same company on our request and given the catalogue number 90357. N-(4-hydroxyphenyl)arachidonylamide (AM404) was purchased from Tocris Cookson (Bristol, U.K.). Fatty acid free bovine serum albumin (BSA) was obtained from the Sigma Chemical Co. (St Louis, MO, U.S.A.). All cell culture media, sera and supplements were from Gibco/Life Technologies.
Synthesis of propanoylethanolamide (C3:0)
In a two-neck¯ask, 14.06 g of ethanolamine (0.23 mol) were poured into 20 ml of dry methylene chloride. The solution was cooled in an ice bath and magnetically stirred. Propionyl chloride (5.325 g, 57 mmol) was added dropwise. The reaction mixture was stirred for 12 h at room temperature, ®ltered, and the ®ltrate was evaporated under reduced pressure. 
Synthesis of butanoylethanolamide (C4:0)
In a two-neck¯ask, 11.76 g of ethanolamine (0.192 mol) were poured into 20 ml of dry methylene chloride. The solution was cooled in an ice bath and magnetically stirred. Butyryl chloride (5.11 g, 48 mmol) was added dropwise. The reaction mixture was stirred for 12 h at room temperature, ®ltered, and the ®ltrate was evaporated under reduced pressure. 
Synthesis of hexanoylethanolamide (C6:0)
In a two-neck¯ask, 1.294 g of 1,1'-carbonyldiimidazole (7.98 mmol) were poured into 20 ml of dry methylene chloride. The solution was cooled in an ice bath and magnetically stirred. Hexanoic acid (0.92 g, 7.98 mmol) was added dropwise. Ethanolamine (1.95 g, 31.9 mmol) was then added to the reaction mixture, which was stirred for 24 h at room temperature. After this incubation, the reaction mixture was washed with water, 10% citric acid solution and NaCl saturated solution and dried (MgSO 4 ) and the solvent was evaporated under reduced pressure. 
Synthesis of octanoylethanolamide (C8:0)
In a two-neck¯ask, 7.35 g of ethanolamine (0.12 mol) were poured into 15 ml of dry methylene chloride. The solution was cooled in an ice bath and magnetically stirred. Octanoyl chloride (1.95 g, 12 mmol) was added dropwise. The reaction mixture was stirred for 12 h at room temperature and then ®ltered. The solid was recrystallized in ethanol-water to give 2.06 g (92% 
Membrane preparation for FAAH assay
Frozen brains (minus cerebellum) stored at 7708C from adult rats were thawed and homogenized at 48C in 20 mM HEPES buer, pH 7.0, with 1 mM MgCl 2 using a glass homogenizer. The homogenates were centrifuged twice at 36,0006g for 20 min at 48C after which the tissue pellets were re-suspended in homogenization buer and incubated at 378C for 15 min. After centrifugation at 36,0006g for 20 min at 48C, membranes were re-suspended in 50 mM Tris-HCl buer, pH 7.4, containing 1 mM EDTA and 3 mM MgCl 2 . The protein content in the membrane preparations were determined according to the method of Harrington (1990) , using bovine serum albumin as standard, and the preparations were stored at 7708C until used for assay.
FAAH assay
The method used was ®rst described by Omeir et al. (1995) ). After vortex mixing of the tubes the phases were separated by centrifugation in a bench centrifuge. Aliquots (200 ml) of the methanol/buer phase were removed and analysed for radioactivity by liquid scintillation spectroscopy with quench correction. Blanks contained distilled water instead of the homogenate preparations.
Radioligand binding experiments
Human CB 1 -(`CHO-CB 1 ') and CB 2 -(`CHO-CB 2 ') transfected CHO cells, kindly donated by Drs Nokin and Detheux (Euroscreen, Belgium) were maintained in culture using Ham's F12 medium containing 10% fetal bovine serum, 100 mg/ml streptomycin, 100 U ml 71 penicillin and 200 mg/ml G418. Membranes (40 mg) and test compounds were incubated at 308C with 1 nM (pH 7.4) in the presence of 50 mM PMSF. Non-speci®c binding was determined with 10 mM HU-210 (CHO-CB 1 ) or 10 mM WIN 55,212-2 (CHO-CB 2 ). After incubation, the membrane suspension was rapidly ®ltered through 0.5% polyethyleneimine-pretreated GF/B glass ®bre ®lters (Whatman), and the radioactivity trapped on the ®lters was measured by liquid scintillation spectroscopy. Assays were undertaken in quadruplicate.
Cell cultures
Rat basophilic leukaemia (RBL-2H3) cells (passage range 14 ± 22) and rat C6 glioma cells (passage range 52 ± 65) were obtained from the American Type Culture Collection, MD, U.S.A. The cells were grown in 75 cm 2 culturing¯asks at 378C, 5% CO 2 in air at normal atmospheric pressure. The cells were cultured in Eagle's minimum essential medium, 2 mM L-glutamine supplemented with 15% foetal bovine serum and 100 units ml 71 penicillin+100 mg ml 71 streptomycin (RBL-2H3) or Ham's F10 medium, supplemented with 10% foetal bovine serum and 100 units ml 71 penicillin+100 mg ml 71 streptomycin (C6). The culture media were changed three times a week. The method developed by Rakhshan et al. (2000) was used. RBL-2H3 or C6 cells were plated on 24 well plates at an initial density of 1.5 ± 2610 5 cells.well 71 and incubated at 378C for 18 h under an atmosphere of 5% CO 2 in air at normal atmospheric pressure. After the incubation period, cells were washed once with 0.5 ml warm assay buer (mM: NaCl 120, KCl 4.7, CaCl 2 2.2, HEPES 10, KH 2 PO 4 1.2, MgSO 4 1.2, pH 7.4; gassed with 95% O 2 , 5% CO 2 ) and preincubated in 350 ml buer with the test compounds or ethanol carrier at 378C for 10 min. [ 3 H]-AEA (50 ml, ®nal concentration 10 mM) was added to the wells and uptake at 378C was allowed for 15 min. After the incubation, the plates were placed on ice after which the cells were rinsed three times with ice-cold buer containing 1% BSA to terminate the transport. The cells were aspirated of the buer and incubated at 758C in 0.2 M NaOH (500 ml well 71 ) for 15 min. Aliquots (300 ml) of the solubilized cells were transferred to scintillation vials and assayed for tritium content by liquid scintillation spectroscopy with quench correction. Test substances and AEA were diluted in ethanol and buer and the ethanol concentration was constant between the dierent wells and never exceeded 5%. Previous experiments using RBL-2H3 cells have demonstrated that this concentration of ethanol does not signi®cantly aect the uptake of [ ) in Ham's F10 medium, supplemented with 1% foetal bovine serum and 100 units ml 71 penicillin+100 mg ml 71 streptomycin. After incubation overnight, the wells were washed once with 400 ml warm assay buer (mM: NaCl 120, KCl 4.7, CaCl 2 2.2, HEPES 10, KH 2 PO 4 1.2, MgSO 4 1.2, pH 7.4; gassed with 95% O 2 , 5% CO 2 ) and preincubated for 10 min at 378C in 350 ml buer plus 25 ml of either carrier (ethanol), test compound or phenylmethylsulphonyl¯uoride (PMSF, 1.5 mM ®nal concentration). [ 3 H]-AEA (25 ml, ®nal concentration 3 mM) was added to the wells. The plates were then incubated for 30 min at 378C with the lids on, after which they were placed on ice and aliquots (400 ml) of methanol added to each well. The wells were scraped and the contents placed in test tubes. Chloroform (200 ml) was added, the test tubes were vortex mixed and centrifuged to separate the phases. Aliquots (200 ml) of the aqueous phase (containing the [ 3 H]-ethanolamine) were taken and counted for radioactivity by scintillation spectroscopy with quench correction. Blanks were de®ned as the radioactivity recovered for samples on a separate plate preincubated with PMSF.
Determination of pI 50 , K i(slope) and K i(intercept) values
pI 50 values [7log 10 (IC 50 value)] were analysed using the built-in equation`sigmoid dose-response (variable slope)' of the GraphPad Prism computer programme (GraphPad Software Inc., San Diego, CA, U.S.A.). Two dierent approaches were used. In order to determine the maximal inhibition produced by the compounds, the data (expressed as per cent of control) were analysed using`top' (i.e. uninhibited) values ®xed at 100. For compounds where the`bottom' values (i.e. minimum activity remaining) were signi®cantly greater than 0 (i.e. when the 95% con®dence intervals of the value were both greater than 0), the pI 50 values (i.e. re¯ecting the potency with respect to the inhibitable fraction of the [ 3 H]-AEA metabolism) were taken from these analyses. For compounds where the 95% con®dence intervals of the minimum activity remaining straddled zero, the pI 50 values were taken from analyses where the bottom value was set to 0. This approach was taken to avoid artefactually low pI 50 values resulting from the use of unrealistic`bottom values'. An example of this would be decanoylethanolamide (C10:0), where the calculated`bottom' value was 7332+1288 (95% con®dence limit 73011 to +2347). Apparent K m and V max values for inhibition of [ 3 H]-AEA metabolism by palmitoylisopropylamide (C16:0) and oleoylethanolamide (C18:1) were calculated from the mean data using the Direct Linear Plot analysis (Eisenthal & Cornish-Bowden, 1974 ) using the Enzyme Kinetics v 1.4 software package, Trinity Software, Campton, NH, U.S.A. These values were then used in secondary replots to determine K i(slope) and K i(intercept) values.
Statistics
ANOVA tests for repeated measures and Bonnferroni-Dunn post hoc tests were conducted using the Statview TM computer programme (SAS Institute Inc., Cary, NC, U.S.A.).
Results
Validation of blank value for assay of FAAH
In the FAAH assay used, blanks are de®ned as the tritium recovered in the aqueous phase following incubation of [ , it was considered to be of importance to con®rm that the blanks determined in this way are valid. To this end, three compounds known to inhibit FAAH, namely arachidonoyl-serotonin, AM404 and arvanil Melck et al., 1999; Jarrahian et al., 2000) and one presumed inhibitor (palmitoyl tri¯uoromethyl ketone, PTMK;`presumed' since the arachidonoyl-and oleoyl-tri¯uoromethyl ketones are highly potent transition-state FAAH inhibitors, Koutek et al., 1994; Patterson et al., 1996) . All four compound produced a complete inhibition of [ C18:0 (stearoylethanolamide) were tested for their ability to prevent [ 3 H]-AEA hydrolysis (Figure 3a,b) . The observed inhibition will re¯ect both the potency and the solubility of the compound, the latter particularly in the case of the longchain compounds. Indeed, our experience is that the solubility of these saturated fatty acid amides can vary from preparation to preparation, due to temperature-dependent polymorphism of the pure crystals (J. Wouters, S. Vandevoorde & D. Lambert, unpublished results) . In order to calculate potencies, the maximum inhibition was calculated and the pI 50 values determined for this inhibitable component. Using this approach, it was seen that complete inhibition of [ 3 H]-AEA could be attained for the compounds with side-chain lengths of 10, 12 and 14 carbon atoms, whereas only partial inhibition (78, 55 and 33% for 16, 17 and 18 carbon atoms, respectively) was seen at longer chain lengths (Table 1) . This partial inhibition presumably re¯ects limited solubility of the compounds rather than the presence of an FAAH enzyme subtype with which the compounds do not interact. In the absence of a preincubation phase, the potencies of the compounds towards the inhibitable component of the activity were similar for the compounds with side chains ranging from 18 to 12 carbon atoms (pI 50 values 4.77 ± 4.95) with the possible exception of palmitoylethanolamide itself (pI 50 value of 5.30). This value for palmitoylethanolamide corresponds to an IC 50 value of 5.1 mM, which is in good agreement with the K M value of this compound as a substrate for rat brain FAAH using the same assay conditions (range 1.3 ± 8.5 mM, Tiger et al., 2000) . For the 10 carbon atom, a lower potency was seen (pI 50 value of 4.26), and for the four compounds with side chain lengths of 8, 6, 4 and 3 carbon atoms, 520% inhibition of [ 3 H]-AEA metabolism was seen at the highest concentration tested (100 mM). Oleoylethanolamide, the mono-unsaturated analogue of stearoylethanolamide, had sucient solubility and was able completely to inhibit [ Table  1 ). The cyclohexamide analogue produced 11% inhibition at the highest concentration tested (100 mM).
The above experiments were undertaken in the absence of preincubation. Two series of experiments were undertaken to determine whether a preincubation of homogenate with test compound aected the observed inhibition of [ 3 H]-AEA uptake. In the ®rst series, dose-response experiments (analogous to those shown in Figures 3 and 4) for all the compounds except stearoyl-and heptadecanolethanolamide were undertaken using a 60 min preincubation phase. With two exceptions, this treatment did not aect the observed maximum inhibition or the potency of the compounds (data not shown). The two exceptions were for palmitoylethanolamide and palmitoylisopropylamide, where the 95% con®dence intervals of the minimum activity remaining straddled zero. In the case of palmitoylethanolamide, the apparent residual activity was 15+8% [95% con®dence intervals 72 to 33] (as opposed to 22+7% (95% con®dence intervals +7 to +37) in the absence of preincubation). The pI 50 value for palmitoylethanolamide was calculated to be 5.12+0.13 assuming a residual inhibition and 4.90+0.06 assuming no residual inhibition. This dierence underlines the importance of regarding the pI 50 values as approximate rather than exact estimates of potency. For palmitoylisopropylamide, the apparent pI 50 value (assuming maximal inhibition) was 4.71+0.05 following a 60 min preincubation period.
In a second experiment, the 10 : 0 ± 16 : 0 ethanolamide compounds, oleoylethanolamide, palmitoylisopropylamide, palmitoylbutylamide and R-palmitoyl-(2-methyl)ethanolamide were pre-incubated for 0, 60, 120 and 180 min at 378C with a stronger homogenate concentration (50 mg protein assay
71
) before being incubated with [ 3 H]-AEA for a shorter time (3 min). Single concentrations of the compounds, chosen to be on the steep part of the concentration-response curve were tested (data not shown). Only lauroylethanolamide (20 mM) exhibited a small, but signi®cant reduction in its ability to prevent AEA hydrolysis as the preincubation time was increased. Thus, the per cent activity remaining following 0, 60, 120 and 180 min of incubation with laurylethanolamide were 51+3, 51+5, 57+1 and 62+4%, respectively (means+s.e.mean, n=3, one-way ANOVA for repeated measures (preincubation time) gave F 3,6 =8.4 (P50.05)). For comparison, 15 mM palmitoylethanolamide gave values of 50+3, 53+1, 58+3 and 53+5%, respectively (means+s.e.mean, n=3, P40.05). The same pattern was seen with lauryethanolamide when a 10 min incubation time and a more dilute homogenate was used (data not shown). Figure 5 . Both compounds acted as mixed-type inhibitors with K i(slope) and K i(intercept) values, respectively of 15 mM and 87 mM (palmitoylisopropylamide) and 3.9 mM and 11 mM for oleoylethanolamide. R-palmitoyl-(2-methyl)ethanolamide was also investigated and found to be a competitive inhibitor with a K i value of 6.6 mM (data not shown).
Interaction of the analogues and homologues of palmitoylethanolamide with cannabinoid CB receptors expressed on CHO cells
As reported in the introduction, most of the compounds selected for this study have been shown not to interact with CB receptors . However, the highest concentration used in that study was 1 mM, raising the possibility that interactions can occur at higher concentrations of the compounds. In consequence, the eects of the compounds at 10 and 100 mM upon the speci®c binding of the synthetic cannabinoid receptor agonist radioligand [ 3 H]-WIN 55,212-2 to recombinant human CB 2 receptors expressed on CHO cells was investigated. With the exception of oleoylethanolamide (65% inhibition at 100 mM), all of the compounds produced 515% inhibition of binding at 10 mM and 525% inhibition at 100 mM (Table 2 ). For the binding of the agonist [ 3 H]-CP55,940 to recombinant human CB 1 receptors expressed on CHO cells, the data was less clear, although 526% inhibition of binding was found at both concentrations for palmitoylethanolamide, R-palmitoyl-(2-methyl)ethanolamide and palmitoylisopropylamide and the C4.0 and C10.0-homologues ( Table 2) . As with the CB 2 receptors, oleoylethanolamide produced a large (63%) inhibition of binding at 100 mM (Table 2 ). (Bisogno et al., 1997; De Petrocellis et al., 2000; Rakhshan et al., 2000; Jacobsson & Fowler, 2001) . Less is known about the uptake of AEA into C6 cells, although there are some apparent dierences in the properties of the transporters in the two cell lines (such as sensitivity to nitric oxide donors, Bisogno et al., 2001; Jacobsson & Fowler, 2001 ). The initial data, shown in Figure 6c , investigated the eects of the palmitoylethanolamide homologues and analogues at concentrations of 1, 10 and 100 mM, to inhibit the uptake of 10 mM In these subsequent experiments, the percentage of the total apparent uptake in RBL-2H3 cells due to the binding of [ 3 H]-AEA to the wells could be determined (52+6%). This Insucient inhibition was obtained to permit meaningful calculation of pI 50 values. In consequence, the observed inhibition at the highest concentration tested has been given instead.
b The calculated bottom value exceeded 100% inhibition (i.e. 50% activity remaining, e.g. 710+35% for myristoylethanolamide). However, since the 95% con®dence intervals of the minimum activity remaining straddled zero (e.g. 782 to +63% for myristoylethanolamide), the pI 50 values were calculated using a ®xed maximum inhibition of 100%.
c 95% con®dence intervals of the minimum activity remaining were both greater than zero (e.g. 37 ± 55% for Rpalmitoyl-(2-methyl)ethanolamide), thus allowing the pI 50 values to be calculated using the maximum inhibition values given. Figure 6c as a dashed line, and was used, in conjunction with experiments undertaken in the absence of cells, to determine the degree to which the compounds at a concentration of 100 mM aected the binding of the [ 3 H]-AEA to the wells. Although the use of a retroactive measure of binding to the wells prevents quantitative interpretation of these data, the ®rst series of experiments indicated that several of the compounds are inactive (i.e. the homologues of palmitoylethanolamide at C48 atoms) at 10 and 100 mM concentrations. Inhibition of [ 3 H]-AEA uptake was seen at 10 mM concentrations with decanoylethanolamide, palmitoylisopropylamide, lauroylethanolamide and myristoylethanolamide, and at 100 mM concentrations with palmitoylethanolamide, palmitoylbutylamide, palmitoylcyclohexamide and oleoylethanolamide (although interpretation of the data with oleoylethanolamide is confounded by its ability to inhibit the binding of [ 3 H]-AEA to the wells). None of the compounds aected the total uptake at concentrations of 1 mM (data not shown).
In the second series of experiments, the eects of palmitoylcyclohexamide and palmitoylisopropylamide (10 and 30 mM) were tested using both C6 and RBL-2H3 cells, and where parallel wells without cells were used to quantify the binding of the [ 3 H]-AEA to the culture wells (Figure 6a) . Propylisopropylamide reduced the speci®c uptake to 66 and 38% of control in the C6 cells at concentrations of 10 and 30 mM, respectively, whereas palmitoylcyclohexamide was less eective (99 and 76%, respectively). Similar results were seen in the RBL-2H3 cells (Figure 6a ). Octanoyethanolamide, palmitoylethanolamide and R-palmitoyl-(2-methyl)ethanolamide at concentrations of 30 mM had no eect on the uptake of [ Table 3 . Oleoylethanolamide and palmitoylisopropylamide were the most potent of the compounds tested, producing 450% and 480% inhibition of [ 3 H]-ethanolamine production at 10 and 30 mM, respectively, in both cases. AM404 was slightly less potent (40 and 68% inhibition at 10 and 30 mM, respectively), whereas palmitoylethanolamide, palmitoylcyclohexamide, R-palmitoyl-(2-methyl)ethanolamide and octanoylethanolamide produced 42, 45, 30 and 25% inhibition, respectively , at the highest concentration tested (30 mM).
Discussion
The fatty acid amide palmitoylethanolamide has been found to have anti-in¯ammatory and anti-nociceptive properties (Aloe et al., 1993; Mazzari et al., 1996; Jaggar et al., 1998; Calignano et al., 1998) . Given that this compound has a low anity towards CB receptors in vitro and produces no signi®cant eects at concentrations 410 mM (Felder et al., 1993; Ross et al., 1999; Sugiura et al., 2000) , it has been suggested that palmitoylethanolamide, by preventing the metabolism of other endocannabinoids, may act as an`entourage' compound (Lambert & Di Marzo, 1999) . The metabolism of AEA is brought about by a process of facilitated diusion into the cell followed by intracellular FAAH-catalysed metabolism (see Mechoulam et al., 1998) . In consequence, we tested both a series of palmitoylethanolamide analogues and homologues, as well as four new homologues (C3:0, C4:0, C6:0 and C8:0) and a 2-methyl analogue, for their ability to aect rat brain FAAH catalysed [ With respect to the ability of the compounds to inhibit the FAAH-catalyzed metabolism of [ 3 H]-AEA, the chain length proved to be of importance for the potency at lengths of 10 carbon atoms or less. Thus, potencies of the homologues were roughly similar (given the approximate nature of the pI 50 values as a result of the dierences in maximum inhibition obtained) to palmitoylethanolamide as the chain length was reduced to 14 and 12 carbon atoms (or increased to 18 carbon atoms), but was slightly lower for the C10:0 compound (decanoylethanolamide). Compounds with a chain length of 48 carbon atoms were inactive. This pattern of stability' between C12:0 and C18:0 is also seen with saturated fatty acid sulphonyl¯uoride compounds, although their potencies are greater than seen here: IC 50 values of 3, 6 and 7 nM for the inhibition of rat brain AEA metabolism by lauryl-(C12), myristyl-(C14), palmityl-(C16) sulphonyl uorides were found (Deutsch et al., 1997) . In contrast, the C20:0 homologue arachidylsulphonyl¯uoride is less potent (IC 50 value 448 nM) (Deutsch et al., 1997) .
Among the C16:0 analogues, palmitoylisopropylamide, Rpalmitoyl-(2-methyl)ethanolamide and palmitoylbutylamide showed comparable potency to that of palmitoylethanolamide, although the maximal obtainable inhibition was lower. Oleoylethanolamide (C18:1) was a mixed type inhibitor of [ 3 H]-AEA metabolism with K i(slope) and K i(intercept) values of 3.9 mM and 11 mM, respectively. Although the maximum observed inhibition produced by this compound was greater than seen with the saturated analogue, stearoylethanolamide, this may re¯ect solubility dierences and the dierence in pI 50 values was not that great. In this respect, the potency of PTMK was very similar to that found previously for its oleoyl-analogue (pI 50 value 7.24+0.077) in experiments using the same experimental conditions, . The potency of PTMK found here is approximately 50 times greater than the potency of this compound towards Ca 2+ -independent phospholipase A2 (Ackermann et al., 1995) , making it worthwhile further to investigate the potential usefulness of this compound as an FAAH inhibitor.
In theory, the palmitoylethanolamide analogues and homologues can inhibit [ 3 H]-AEA metabolism by acting either as inhibitors or as competing substrates. Indeed, amidase activities capable of utilizing C12:0 ± C18:0 (but not C8:0) and C18:1 ethandamides as substrates were reported in the literature more than 16 years ago (Natarajan et al., 1984; Schmid et al., 1985) . Most available studies in the literature have compared the relative activities of palmitoylethanolamide with AEA with widely varying results (see Tiger et al., 2000) , although Lang et al. (1999) found a 4 fold greater rate of metabolism of 100 mM oleoylethanolamide than 100 mM stearoylethanolamide using rat brain microsomes as source of FAAH. There is more data on the ability of 7amide, rather than 7ethanolamide compounds to act as substrates. Thus, palmitoylamide (C16:0), myristoylamide (C14:0) and dodecanoylamide (C12:0) have been shown to act as FAAH substrates with rates of hydrolysis relative to oleamide (C18:1) of 0.72, 0.83 and 0.74, respectively (Boger et al., 2000a ; see also Cravatt et al., 1996) . These authors also demonstrated that introduction of a single double-bond into the 9-position of the palmitoylamide and myristoylamide molecules did not aect their rates of hydrolysis, whereas the mono-unsaturated oleamide was metabolized at a higher rate than the saturated stearamide equivalent (Boger et al., 2000a) . These authors used single high concentrations of substrate (187 mM), thus presumably measuring activities near their V max values. Given (a) that linoleoylethanolamide and linoleoylamide are both substrates for FAAH and are metabolized with similar V max values (Maurelli et al., 1995); and (b) . Whether the`non-competitive component' of the inhibition in these cases represents an additional action of the compounds (such as eects secondary to membrane actions of these fatty acid amides) awaits elucidation.
For the palmitoylethanolamide analogues tested here, it is not known whether they are substrates for FAAH. One way of distinguishing inhibitors from competing substrates is to preincubate the compounds with a strong FAAH preparation prior to addition of [
